Intravenous Ustekinumab for Inflammatory Bowel Disease
Customize your policy alerts
Sign up for all Bluecross Idaho policy alerts
Know when Bluecross Idaho releases new policies or updates existing guidance.
Monitor payer policy activity
Medical-benefit coverage and prior authorization for intravenous ustekinumab induction in adults with moderately to severely active Crohn's disease or ulcerative colitis; subcutaneous ustekinumab is handled under the pharmacy benefit.
The policy added HCPCS code J3590 for unclassified biologics and identified Yesintek (ustekinumab-kfce) in the 2026 medical-benefit update.
The policy history states that the policy was extensively revised and that language was updated for consistency across policies.
OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.